That means freeloaders.

Germany’s new drug law is a case study in foreign freeloading – U.S. patients will bear even more of the global bill.

At the very moment President Donald J. Trump is demanding that wealthy nations pay their fair share for American medicines, Berlin moved the other way. Its new cost-containment law squeezes more savings from the American companies that discover these medicines and leaves U.S. patients bearing even more of the global bill.

The German parliament passed the law last month. It more than doubles the mandatory rebate that manufacturers pay on brand-name medicines, from 7% to 15.5%. It locks German list prices in place through 2030. And for the first time, it lets German insurers force patented, brand-name medicines into tender-style price competitions — a tactic Germany had reserved for generic drugs until now. Berlin called it a fix for its strained insurance system. In plain terms, it is a wealthy nation balancing its books on the backs of American patients.